GlassScriptPhysician profile
David Adrian Garza
NPI 1194721423
$11,004.81
in general payments reported to CMS, 2019-2025
25 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $133 · 2021: $366 · 2022: $1,373 · 2023: $4,227 · 2024: $3,325 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,375 · Food and Beverage: $3,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,375.00 |
| Food and Beverage | $3,366.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $5,901.05 | 2022-2025 | Clariti Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $1,058.47 | 2019-2025 | Total30, Precision7, Tryptyr |
| Abbvie INC. | $743.17 | 2022-2025 | |
| Glaukos Corporation | $618.66 | 2022-2025 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idosetr |
| Bausch & Lomb Americas INC. | $605.10 | 2022-2025 | Infuse, Vyzulta, Xiidra |
| Johnson & Johnson Vision Care, INC. | $392.71 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $285.47 | 2024-2025 | Xdemvy |
| Allergan, INC. | $185.94 | 2021-2022 | |
| Rxsight INC | $182.26 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $167.97 | 2019-2025 | Cequa |
| Dompe US, INC. | $141.25 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $119.34 | 2019-2023 | |
| Oyster Point Pharma, INC. | $100.82 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $76.21 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $68.85 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $53.16 | 2020 | |
| Astellas Pharma US INC | $46.80 | 2025 | Izervay |
| Axsome Therapeutics, INC. | $28.96 | 2025 | Symbravo |
| Shire North American Group INC | $23.94 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $18.85 | 2025 | Forum |
| Johnson & Johnson Surgical Vision, INC. | $18.32 | 2020 | |
| Sight Sciences, INC. | $15.89 | 2022 | |
| Eyepoint US, INC. | $14.36 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.